InSea2(TM) new human study supports its role as the next generation of Carb/Starch control ingredients

Rimouski (Quebec), December 1st, 2009 – innoVactiv inc., a Canadian company dedicated to
developing science-based ingredients, is pleased to report that InSea2™ produced statistically
significant results in a recently completed human clinical trial. The aim of the study was to test
the ability of InSea2™ to lower serum glucose levels and insulin response versus placebo that
follow ingestion of a test food. Given the positive results from the study, InSea2™ represents a
new breed of carb/starch control ingredients in the dietary supplement market and offers
consumers a tool that can provide unsurpassed control over the normal blood sugar and insulin
response to a meal.

In a randomized crossover, double-blinded, placebo-controlled human clinical trial led by the
Institute of Nutraceuticals and Functional Foods of Laval University (Quebec, Canada), InSea2™
(at a single dose of 500 mg) induced a statistically significant 44% decrease in the normal
glycemic response that follows ingestion of a standardized meal (white bread, P=0.046) in
twenty-three healthy volunteers. InSea2™ also induced a 22% reduction in initial insulin
production (P=0.045) and an overall 5.9% reduction in the area under the curve of the insulin
response (P=0.031). Even more interesting was the fact that InSea2™ improved insulin sensitivity
by 6.9% (Cederholm index, P=0.047) after a single use of the product. The results of this study
will be presented at the Experimental Biology meeting in Anaheim, CA, April 24-28, 2010.
“We are very excited by these results, confirming the efficacy of InSea2™ in humans. The fact
that we reached statistically significant results at low dosage levels is encouraging, especially
from a pure science perspective. The study demonstrates that InSea2™ and its dual mechanism
of action may offer a superior efficacy compared to other ingredients that block only one of the
two enzymes involved in carb digestion” says Jocelyn Bérubé, Scientific Director, Health &
Nutrition at innoVactiv.

InSea2™ is the only safe and natural ingredient that offers a dual mechanism of action targeting
carbohydrate digestion. It works by inhibiting both α-amylase and α-glucosidase enzymes, a
process which may lead to a more effective blockage than simple α-amylase or α-glucosidase
inhibitors currently on the market. Alpha-amylase and α-glucosidase are respectively known for
breaking down complex starches into smaller oligosaccharides, and for digesting
oligosaccharides and disaccharides such as table sugar into simple glucose for absorption.
“We could not be happier with the results of this study, which provides substantial evidence on
the efficacy of InSea2™ in improving the management of blood sugar. These new human data on
InSea2™ really bring innoVactiv at the forefront of science-based ingredients suppliers. This fits
with our strategic vision of nurturing long-term partnerships with companies that use scientifically
proven ingredients to drive new product development. Our goal is to ultimately provide the
consumer with a top-shelf product that helps safely improve their health and quality of life,”
added Patrice Dionne, Chief Executive Officer of innoVactiv.

About innoVactiv
innoVactiv’s mission is to develop and supply innovative ingredients whose efficacy and safety
have been scientifically demonstrated. In addition to its two newest nutraceutical active
ingredients, InSea2™ and PeptiBal™, innoVactiv has developed a line of 16 cosmeceutical
ingredients and holds a strong development pipeline of additional ingredients that will offer
solutions for maintaining optimal human health. For more information on innoVactiv, please
contact Patrice Dionne, Chief Executive Officer: [email protected] or visit

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.